adenine has been researched along with Central Nervous System Diseases in 8 studies
Central Nervous System Diseases: Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Hermansson, L | 1 |
| Yilmaz, A | 1 |
| Price, RW | 1 |
| Nilsson, S | 1 |
| McCallister, S | 1 |
| Makadzange, T | 1 |
| Das, M | 1 |
| Zetterberg, H | 1 |
| Blennow, K | 1 |
| Gisslen, M | 1 |
| Lim, KJC | 1 |
| Tam, CS | 2 |
| Hiemcke-Jiwa, LS | 1 |
| Leguit, RJ | 1 |
| Radersma-van Loon, JH | 1 |
| Westerweel, PE | 1 |
| Rood, JJM | 1 |
| Doorduijn, JK | 1 |
| Huibers, MMH | 1 |
| Minnema, MC | 1 |
| Cabannes-Hamy, A | 1 |
| Lemal, R | 1 |
| Goldwirt, L | 1 |
| Poulain, S | 1 |
| Amorim, S | 1 |
| Pérignon, R | 1 |
| Berger, J | 1 |
| Brice, P | 1 |
| De Kerviler, E | 1 |
| Bay, JO | 1 |
| Sauvageon, H | 1 |
| Beldjord, K | 1 |
| Mourah, S | 1 |
| Tournilhac, O | 1 |
| Thieblemont, C | 1 |
| Kimber, T | 1 |
| Seymour, JF | 1 |
| Scourfield, A | 1 |
| Zheng, J | 1 |
| Chinthapalli, S | 1 |
| Waters, L | 1 |
| Martin, T | 1 |
| Mandalia, S | 1 |
| Nelson, M | 1 |
| Benke, PJ | 1 |
| Herrick, N | 1 |
| Smitten, L | 1 |
| Aradine, C | 1 |
| Laessig, R | 1 |
| Wolcott, GJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects[NCT01815736] | Phase 3 | 1,443 participants (Actual) | Interventional | 2013-03-27 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01815736)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF | 90.6 |
| Stay on Baseline Treatment Regimen (SBR) | 85.3 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01815736)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF | 92.8 |
| Stay on Baseline Treatment Regimen (SBR) | 89.1 |
The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen. (NCT01815736)
Timeframe: Baseline; Week 96
| Intervention | cells/uL (Mean) | |
|---|---|---|
| Baseline | Change at Week 96 | |
| E/C/F/TAF | 701 | 60 |
| Stay on Baseline Treatment Regimen (SBR) | 689 | 42 |
The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen. (NCT01815736)
Timeframe: Baseline; Week 48
| Intervention | cells/uL (Mean) | |||
|---|---|---|---|---|
| Baseline (NDA Data Cut) | Change at Week 48 (NDA Data Cut) | Baseline (All Participants) | Change at Week 48 (All Participants) | |
| E/C/F/TAF | 712 | 33 | 701 | 35 |
| Stay on Baseline Treatment Regimen (SBR) | 690 | 27 | 689 | 24 |
(NCT01815736)
Timeframe: Baseline; Week 48
| Intervention | mg/dL (Mean) | |
|---|---|---|
| NDA Data Cut | All Participants | |
| E/C/F/TAF | -0.01 | 0.00 |
| Stay on Baseline Treatment Regimen (SBR) | 0.04 | 0.03 |
"The mean (SD) change of the overall EFV-related symptom assessment score is presented. The overall symptom score (ranging from 0 to 20) is the sum of the individual symptom scores ranging from 0 (no symptoms) to 4 (most severe symptoms) from the 5 EFV-related symptom assessments (dizziness, trouble sleeping, impaired concentration, sleepiness, and abnormal or vivid dream). A negative change from baseline indicates improvement.~EFV-Related Symptom Analysis Set: participants who received EFV/FTC/TDF as prior treatment, received at least 1 dose of study drug, and completed EFV-related symptom assessments at the baseline visit and at least 1 postbaseline visit." (NCT01815736)
Timeframe: Baseline; Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| NDA Data Cut | All Participants | |
| E/C/F/TAF | -1.6 | -1.5 |
| Stay on Baseline Treatment Regimen (SBR) | -0.1 | -0.1 |
Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. BMD is calculated as grams per square centimeter (g/cm^2); the mean (SD) percentage change is presented. (NCT01815736)
Timeframe: Baseline; Week 48
| Intervention | percentage change (Mean) | |
|---|---|---|
| NDA Data Cut | All Participants | |
| E/C/F/TAF | 1.949 | 1.468 |
| Stay on Baseline Treatment Regimen (SBR) | -0.136 | -0.340 |
Spine BMD was assessed by DXA scan. BMD is calculated as g/cm^2; the mean (SD) percentage change is presented. (NCT01815736)
Timeframe: Baseline; Week 48
| Intervention | percentage change (Mean) | |
|---|---|---|
| NDA Data Cut | All Participants | |
| E/C/F/TAF | 1.861 | 1.557 |
| Stay on Baseline Treatment Regimen (SBR) | -0.110 | -0.443 |
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01815736)
Timeframe: Week 48
| Intervention | percentage of participants (Number) | |
|---|---|---|
| NDA Data Cut | All Participants | |
| E/C/F/TAF | 92.2 | 93.5 |
| Stay on Baseline Treatment Regimen (SBR) | 90.4 | 90.4 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01815736)
Timeframe: Week 48
| Intervention | percentage of participants (Number) | |
|---|---|---|
| NDA Data Cut | All Participants | |
| E/C/F/TAF | 95.6 | 97.2 |
| Stay on Baseline Treatment Regimen (SBR) | 92.9 | 93.1 |
1 review available for adenine and Central Nervous System Diseases
| Article | Year |
|---|---|
Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Atrial Fibrillation; Benzamides | 2020 |
1 trial available for adenine and Central Nervous System Diseases
| Article | Year |
|---|---|
Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Central Nervous System Diseases; Creatinine; Drug Administ | 2019 |
6 other studies available for adenine and Central Nervous System Diseases
| Article | Year |
|---|---|
Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement.
Topics: Adenine; Cell Transformation, Neoplastic; Central Nervous System Diseases; Female; Humans; Middle Ag | 2018 |
Efficacy of ibrutinib in the treatment of Bing-Neel syndrome.
Topics: Adenine; Aged; Central Nervous System Diseases; Female; Humans; Immunoglobulin M; Leukocyte Count; M | 2016 |
Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia.
Topics: Adenine; Aged; Central Nervous System Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male | 2017 |
Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; California; Central Nervous Sys | 2012 |
Three new drugs for HIV infection.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Did | 1998 |
Adenine and folic acid in the Lesch-Nyhan syndrome.
Topics: Adenine; Animals; Carbon Radioisotopes; Central Nervous System Diseases; Cricetinae; Depression, Che | 1973 |